Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation ...
Invivyd, Inc. announced dosing of the first participants in the Phase 1 clinical trial of VYD2311, a next-gen mAb candidate for COVID-19, showing high in vitro neutralization potency against post-Omicron variants. The trial, conducted in Australia, will evaluate safety, tolerability, pharmacokinetics, and immunogenicity of VYD2311, with preliminary data expected in Q4 2024. VYD2311 was discovered via affinity maturation against recent SARS-CoV-2 variants and is designed for intramuscular administration for patient convenience. The company also highlighted PEMGARDA™, an investigational mAb authorized for emergency use by the FDA for pre-exposure prophylaxis of COVID-19 in immunocompromised patients.
Related Clinical Trials
Reference News
Invivyd, Inc. announced dosing of first participants in Phase 1 trial of VYD2311, a next-gen mAb candidate for COVID-19, showing high in vitro neutralization potency against post-Omicron variants. The trial, conducted in Australia, aims to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of VYD2311 through various routes of administration, including intramuscular. Preliminary data expected in Q4 2024, with further readouts anticipated throughout 2025.
Invivyd, Inc. announced dosing of the first participants in the Phase 1 clinical trial of VYD2311, a next-gen mAb candidate for COVID-19, showing high in vitro neutralization potency against post-Omicron variants. The trial, conducted in Australia, will evaluate safety, tolerability, pharmacokinetics, and immunogenicity of VYD2311, with preliminary data expected in Q4 2024. VYD2311 was discovered via affinity maturation against recent SARS-CoV-2 variants and is designed for intramuscular administration for patient convenience. The company also highlighted PEMGARDA™, an investigational mAb authorized for emergency use by the FDA for pre-exposure prophylaxis of COVID-19 in immunocompromised patients.